Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how the use of an immuno-PET antibody composed of the native daratumumab labelled with the positron-emitting radionuclide zirconium-89, through the chelator deferoxamine, or 89Zr-DFO-daratumumab, demonstrated successful uptake in osseous deposits in patients with multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).